Congenital Adrenal Hyperplasia Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight| Becton, Dickinson and Company, Cook Medical, Cooper Surgical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Congenital Adrenal Hyperplasia pipeline constitutes 5+ key companies continuously working towards developing 8+ Congenital Adrenal Hyperplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Congenital Adrenal Hyperplasia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Congenital Adrenal Hyperplasia Market.

The Congenital Adrenal Hyperplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Congenital Adrenal Hyperplasia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-pipeline-insight [https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key takeaways from the Congenital Adrenal Hyperplasia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Congenital Adrenal Hyperplasia treatment therapies with a considerable amount of success over the years.

*
Congenital Adrenal Hyperplasia companies working in the treatment market are Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others, are developing therapies for the Congenital Adrenal Hyperplasia treatment

*
Emerging Congenital Adrenal Hyperplasia therapies in the different phases of clinical trials are- Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others are expected to have a significant impact on the Congenital Adrenal Hyperplasia market in the coming years.

*
In January 2026, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that PALSONIFY generated over $5 million in unaudited preliminary U.S. net product revenue for Q4 2025. The company also reported positive topline results from the fourth cohort of its Phase 2 study of investigational atumelnant, a novel once-daily oral ACTH receptor antagonist being developed to treat classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome.

*
In August 2025, Crinetics Pharmaceuticals (Nasdaq: CRNX) reported that the FDA has awarded Orphan Drug Designation to atumelnant, a novel, first-in-class oral ACTH receptor antagonist taken once daily, for the treatment of classic congenital adrenal hyperplasia (CAH).

*
In June 2025, Lundbeck reported receiving ODD in the US and EU for Lu AG13909 in CAH, highlights its potential in CAH and reinforces regulatory support for advancing innovative therapies in rare endocrine disorders.

*
In May 2025, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has released new findings from its Phase 3 CAHtalyst Trademark Adult and Pediatric trials evaluating CRENESSITY Trademark (crinecerfont). The results revealed that a significant number of pediatric patients with classic congenital adrenal hyperplasia (CAH) reached glucocorticoid doses within the physiological range and achieved normal androstenedione levels. Furthermore, adult male patients showed improvements in certain reproductive hormone levels. Both groups adults and children experienced notable reductions in glucocorticoid dosing. These findings were shared at the 2025 Annual Meeting of the American Association of Clinical Endocrinology in Orlando.

*
In December 2024, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced that the U.S. Food and Drug Administration has approved CRENESSITY Trademark (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement therapy for managing androgens in adults and pediatric patients aged four years and older with classic congenital adrenal hyperplasia (CAH), a rare, serious, and lifelong genetic disorder affecting the adrenal glands. CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, and it is the first and only treatment for classic CAH that directly reduces excess adrenocorticotropic hormone (ACTH) and adrenal androgen production, enabling a reduction in glucocorticoid doses. This marks a significant advancement in the treatment options available for classic CAH.

*
In December 2024, Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for neurological and endocrine disorders with substantial unmet medical needs, has announced the topline results from its CAHmelia-204 study of tildacerfont in adults with congenital adrenal hyperplasia (CAH), as well as its CAHptain-205 study of tildacerfont in both adult and pediatric CAH patients.

Congenital Adrenal Hyperplasia Overview

Congenital Adrenal Hyperplasia (CAH) is a group of genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone, and androgens. CAH is caused by mutations in genes responsible for enzyme production, most commonly 21-hydroxylase. This enzyme deficiency leads to hormone imbalances, resulting in symptoms like abnormal genital development, early puberty, salt-wasting crises, or excessive androgen production. The severity of CAH varies, with "classic" forms being more severe and "non-classic" forms milder. Treatment typically involves hormone replacement therapy to manage symptoms and prevent complications.

Stay ahead of emerging therapies and key developments in Congenital Adrenal Hyperplasia with comprehensive pipeline insights, trends, and market analysis, Congenital Adrenal Hyperplasia Clinical Trials Analysis [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Congenital Adrenal Hyperplasia Drugs Under Different Phases of Clinical Development Include:

*
Tebipenem Pivoxil Hydrobromide (SPR994): Spero Therapeutics

*
Cefepime/zidebactam (WCK-5222): Wockhardt

*
Cefepime/taniborbactam: Venatorx Pharmaceuticals

*
Tildacerfont: Spruce Biosciences

*
NBI-74788 Neurocrine Bioscience

*
BBP-631: BridgeBio Pharma

*
CRN04894: Crinetics Pharmaceuticals Inc.

*
SPR001: Spruce Biosciences

*
Crinecerfont: Neurocrine Biosciences

*
ATR-101: Millendo Therapeutics, Inc.

*
AAV BBP-631: Adrenas Therapeutics Inc

*
Chronocort: Diurnal Limited

*
Osilodrostat: Novartis

Congenital Adrenal Hyperplasia Route of Administration

Congenital Adrenal Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Congenital Adrenal Hyperplasia Molecule Type

Congenital Adrenal Hyperplasia Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Congenital Adrenal Hyperplasia Pipeline Therapeutics Assessment

*
Congenital Adrenal Hyperplasia Assessment by Product Type

*
Congenital Adrenal Hyperplasia By Stage and Product Type

*
Congenital Adrenal Hyperplasia Assessment by Route of Administration

*
Congenital Adrenal Hyperplasia By Stage and Route of Administration

*
Congenital Adrenal Hyperplasia Assessment by Molecule Type

*
Congenital Adrenal Hyperplasia by Stage and Molecule Type

DelveInsight's Congenital Adrenal Hyperplasia Report covers around 8+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Congenital Adrenal Hyperplasia product details are provided in the report. Download the Congenital Adrenal Hyperplasia pipeline report to learn more about the emerging Congenital Adrenal Hyperplasia therapies [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Congenital Adrenal Hyperplasia Therapeutics Market include:

Key companies developing therapies for Congenital Adrenal Hyperplasia are - Medline Industries, Becton, Dickinson and Company, Cook Medical, Cooper Surgical, Smiths Medical, Rocket Medical Plc, CENTOGENE N.V, Eurofins Scientific, PerkinElmer Inc, and others.

Congenital Adrenal Hyperplasia Pipeline Analysis:

The Congenital Adrenal Hyperplasia pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Congenital Adrenal Hyperplasia with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Congenital Adrenal Hyperplasia Treatment.

*
Congenital Adrenal Hyperplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Congenital Adrenal Hyperplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Congenital Adrenal Hyperplasia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Congenital Adrenal Hyperplasia drugs and therapies [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Congenital Adrenal Hyperplasia Pipeline Market Drivers

*
Advancements in Genetic Research, Innovative Therapeutics, Regulatory Support, Investment and Funding, Technological Advancements, are some of the important factors that are fueling the Congenital Adrenal Hyperplasia Market.

Congenital Adrenal Hyperplasia Pipeline Market Barriers

*
However, High Development Costs, Regulatory Challenges, Limited Patient Population, Complexity of the Disease, Competition and Market Saturation, and other factors are creating obstacles in the Congenital Adrenal Hyperplasia Market growth.

Scope of Congenital Adrenal Hyperplasia Pipeline Drug Insight

*
Coverage: Global

*
Key Congenital Adrenal Hyperplasia Companies: Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others

*
Key Congenital Adrenal Hyperplasia Therapies: Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others

*
Congenital Adrenal Hyperplasia Therapeutic Assessment: Congenital Adrenal Hyperplasia current marketed and Congenital Adrenal Hyperplasia emerging therapies

*
Congenital Adrenal Hyperplasia Market Dynamics: Congenital Adrenal Hyperplasia market drivers and Congenital Adrenal Hyperplasia market barriers

Request for Sample PDF Report for Congenital Adrenal Hyperplasia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Congenital Adrenal Hyperplasia Report Introduction

2. Congenital Adrenal Hyperplasia Executive Summary

3. Congenital Adrenal Hyperplasia Overview

4. Congenital Adrenal Hyperplasia- Analytical Perspective In-depth Commercial Assessment

5. Congenital Adrenal Hyperplasia Pipeline Therapeutics

6. Congenital Adrenal Hyperplasia Late Stage Products (Phase II/III)

7. Congenital Adrenal Hyperplasia Mid Stage Products (Phase II)

8. Congenital Adrenal Hyperplasia Early Stage Products (Phase I)

9. Congenital Adrenal Hyperplasia Preclinical Stage Products

10. Congenital Adrenal Hyperplasia Therapeutics Assessment

11. Congenital Adrenal Hyperplasia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Congenital Adrenal Hyperplasia Key Companies

14. Congenital Adrenal Hyperplasia Key Products

15. Congenital Adrenal Hyperplasia Unmet Needs

16 . Congenital Adrenal Hyperplasia Market Drivers and Barriers

17. Congenital Adrenal Hyperplasia Future Perspectives and Conclusion

18. Congenital Adrenal Hyperplasia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=congenital-adrenal-hyperplasia-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-becton-dickinson-and-company-cook-medical-cooper-surgical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.